CAS 70-51-9

Deferoxamina

Descrizione:

Deferoxamina è un agente chelante utilizzato principalmente nel trattamento delle condizioni di sovraccarico di ferro, come quelle derivanti da trasfusioni di sangue ripetute in pazienti con condizioni come talassemia o anemia falciforme. È un ligando esadentato, il che significa che può formare più legami con un singolo ione metallico, legandosi specificamente agli ioni ferrici (Fe³⁺) per facilitare la loro escrezione dal corpo. Deferoxamina viene tipicamente somministrato per via sottocutanea o endovenosa, poiché è scarsamente assorbito dal tratto gastrointestinale. Il composto è caratterizzato dalla sua capacità di formare complessi stabili con il ferro, il che aiuta a ridurre la tossicità del ferro e prevenire danni agli organi. Oltre ai suoi usi terapeutici, Deferoxamina è stato studiato per le sue potenziali proprietà antiossidanti e il suo ruolo in varie applicazioni di ricerca. La sua struttura chimica include un gruppo funzionale acido idrossamico, che è cruciale per le sue proprietà chelanti. In generale, Deferoxamina svolge un ruolo vitale nella gestione del sovraccarico di ferro e nel miglioramento dei risultati dei pazienti in specifici disturbi ematologici.

Formula: C₂₅H₄₈N₆O₈

InChI: InChI=1/C25H48N6O8/c1-21(32)29(37)18-9-3-6-16-27-22(33)12-14-25(36)31(39)20-10-4-7-17-28-23(34)11-13-24(35)30(38)19-8-2-5-15-26/h37-39H,2-20,26H2,1H3,(H,27,33)(H,28,34)

InChI key: InChIKey=UBQYURCVBFRUQT-UHFFFAOYSA-N

SMILES: C(CCC(NCCCCCN(C(C)=O)O)=O)(N(CCCCCNC(CCC(N(CCCCCN)O)=O)=O)O)=O

Sinonimi:

• 3,9,14,20,25-Pentaazatriacontane-2,10,13,21,24-pentone, 30-amino-3,14,25-trihydroxy-
• 30-Amino-3,14,25-trihydroxy-3,9,14,20,25 pentaazatriacontane-2,10,13,21,24-pentaone
• Butanediamide, N'-[5-[[4-[[5-(acetylhydroxyamino)pentyl]amino]-1,4-dioxobutyl]hydroxyamino]pentyl]-N-(5-aminopentyl)-N-hydroxy-
• Butanediamide, N⁴-[5-[[4-[[5-(acetylhydroxyamino)pentyl]amino]-1,4-dioxobutyl]hydroxyamino]pentyl]-N¹-(5-aminopentyl)-N¹-hydroxy-
• Deferoxamin
• Deferoxamina
• Deferoxamine B
• Deferriferrioxamine B
• Deferrioxamine
• Deferrioxamine B
• Desferan
• Desferex
• Desferin
• Desferioxamine B
• Desferoxime
• Desferrin
• Desferrioxamine
• Desferrioxamine B
• Dfo-B
• N'-{5-[acetyl(hydroxy)amino]pentyl}-N-[5-({4-[(5-aminopentyl)(hydroxy)amino]-4-oxobutanoyl}amino)pentyl]-N-hydroxybutanediamide
• N-[5-[3-[(5-Aminopentyl)hydroxycarbamoyl]propionamido]pentyl]-3-[[5-(N-hydroxyacetamido)pentyl]carbamoyl]propionohydroxamic acid
• N⁴-[5-[[4-[[5-(Acetylhydroxyamino)pentyl]amino]-1,4-dioxobutyl]hydroxyamino]pentyl]-N¹-(5-aminopentyl)-N¹-hydroxybutanediamide
• Nsc 527604
• N′-[5-[Acetyl(hydroxy)amino]pentyl]-N-7-[5-([4-[(5-aminopentyl)(hydroxy)amino]-4-oxobutanoyl]amino)pentyl]-N-hydroxysuccinamide
• Propionohydroxamic acid, N-[5-[3-[(5-aminopentyl)hydroxycarbamoyl]propionamido]pentyl]-3-[[5-(N-hydroxyacetamido)pentyl]carbamoyl]-
• N4-[5-[[4-[[5-(Acetylhydroxyamino)pentyl]amino]-1,4-dioxobutyl]hydroxyamino]pentyl]-N1-(5-aminopentyl)-N1-hydroxybutanediamide
• Butanediamide, N4-[5-[[4-[[5-(acetylhydroxyamino)pentyl]amino]-1,4-dioxobutyl]hydroxyamino]pentyl]-N1-(5-aminopentyl)-N1-hydroxy-
• n-[5-[3-[(5-aminopentyl)hydroxycarbamoyl]propionamido]pentyl]-3-[[5-(n-hydroxy
• ba-33112
• deferoxaminum
• n’-[5-[[4-[[5-(acetylhydroxamino)pentyl]amino]-1,4-dioxobutyl]hydroxyamino]pen
• N1-(5-aminopentyl)-N1-hydroxy-N4-(5-(N-hydroxy-4-((5-(N-hydroxyacetamido)pentyl)amino)-4-oxobutanamido)pentyl)succinamide
• butanediamide,n’-(5-((4-((5-(acetylhydroxyamino)pentyl)amino)-1,4-dioxobutyl)h
• deferoxamideb
• entaone
• 1-amino-6,17-dihydroxy-7,10,18,21-tetraoxo-27-(n-acetylhydroxylamino)-6,11,17,
• acetamido)pentyl]carbamoyl]propionohydroxamicacid
• N'-[5-[acetyl(hydroxy)amino]pentyl]-N-[5-[[4-[5-aminopentyl(hydroxy)amino]-4-keto-butanoyl]amino]pentyl]-N-hydroxy-succinamide
• n-benzoyl-ferrioxamine
• Deferoxamine USP/EP/BP
• taone
• 3,9,14,20,25-pentaazatriacontane-2,10,13,21,24-pentone,30-amino-3,14,25-trihyd
• N1-(5-Aminopentyl)-N1-hydroxy-N4-(5-(N-hydroxy-4-((5-(N-hydroxyacetamido)-pentyl)amino)-4-oxobuta
• deferoxamine
• deferoxamineb
• desferrioxamineb
• 3,9,14,20,25-pentaazatriacontane-2,10,13,21,24-pentone,30-amino-3,14,25-trih
• ba-29837
• tyl]-n-(5-aminopentyl)-n-hydroxybutanediamide
• deferrioxamineb
• desferriferrioxaminb
• 30-amino-3,14,25-trihydroxy-3,9,14,20,25-pentaazatriacontane-2,10,13,21,24-p
• 30-amino-3,14,25-trihydroxy-3,9,14,20,25-pentaazatriacontane-2,10,13,21,24-pen
• ba33112
• N'-{5-[ACETYL(HYDROXY)AMINO]PENTYL}-N-[5-({4-[(5-AMINOPENTYL)(HYDROXY)AMINO]-4-OXOBUTANOYL}AMINO)PENTYL]-N-HYDROXYSUCCINAMIDE
• N'-[5-[[4-[[5-(Acetylhydroxyamino)pentyl]amino]-1,4-dioxobutyl]hydroxyamino]pentyl]-N-(5-aminopentyl)-N-hydroxysuccinamide
• N-[5-[[4-[5-azanylpentyl(hydroxy)amino]-4-oxo-butanoyl]amino]pentyl]-N'-[5-[ethanoyl(hydroxy)amino]pentyl]-N-hydroxy-butanediamide
• 22-tetraazaheptaeicosane
• n-benzoylferrioxamineb
• DESFEROXAMINE
• DESFERROXAMINE
• desferral
• ydroxyamino)pentyl)-n-(5-aminopentyl)-n-hydroxy-
• dfoa

Deferoxamine Mesylate

CAS: 138-14-7, 70-51-9

Formula: C₂₅H₄₈N₆O₈·CH₄O₃S

Purezza: >97.0%(T)(HPLC)

Colore e forma: White to Light yellow powder to crystal

Peso molecolare: 656.79

Ref: 3B-D4245

Deferoxamine

CAS: 70-51-9

Deferoxamine (Desferrioxamine B) is an iron chelator. Deferoxamine has antioxidant, anti-proliferative and anti-tumor activities. High-Quality, Low-Cost!

Formula: C₂₅H₄₈N₆O₈

Purezza: 99.66% - 99.97%

Colore e forma: Solid

Peso molecolare: 560.68

Ref: TM-T124358

N1-(5-Aminopentyl)-N1-hydroxy-N4-(5-(N-hydroxy-4-((5-(N-hydroxyacetamido)pentyl)amino)-4-oxobutanamido)pentyl)succinamide

CAS: 70-51-9

Formula: C₂₅H₄₈N₆O₈

Purezza: 98%

Colore e forma: Solid

Peso molecolare: 560.6840

Ref: IN-DA005IGL

Deferoxamine

CAS: 70-51-9

Deferoxamine

Purezza: ≥98%

Peso molecolare: 560.68g/mol

Ref: 54-BUP04137

Deferoxamine

CAS: 70-51-9

Deferoxamine is a polymerase chain inhibitor that binds to the folate receptor, a protein on the surface of cells. It is used as an antidote to poisoning by iron, arsenic, and other metals. Deferoxamine also has antioxidant properties and can be used in the treatment of iron overload diseases such as hemochromatosis. Deferoxamine-iron complexes are excreted in the urine, which may be useful for monitoring iron homeostasis. This drug is not active against squamous cell carcinomas or wild-type strains of bacteria that do not have a functional folate receptor.

Formula: C₂₅H₄₈N₆O₈

Purezza: Min. 95%

Colore e forma: Solid

Peso molecolare: 560.68 g/mol

Ref: 3D-FD46531